203 related articles for article (PubMed ID: 12767466)
21. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.
Moyle G
Clin Ther; 2000 Aug; 22(8):911-36; discussion 898. PubMed ID: 10972629
[TBL] [Abstract][Full Text] [Related]
22. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.
Nolan D; Hammond E; Martin A; Taylor L; Herrmann S; McKinnon E; Metcalf C; Latham B; Mallal S
AIDS; 2003 Jun; 17(9):1329-38. PubMed ID: 12799554
[TBL] [Abstract][Full Text] [Related]
23. Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients.
Maagaard A; Holberg-Petersen M; Kvittingen EA; Sandvik L; Bruun JN
HIV Med; 2006 Jan; 7(1):53-8. PubMed ID: 16313293
[TBL] [Abstract][Full Text] [Related]
24. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy.
Haugaard SB; Andersen O; Pedersen SB; Dela F; Richelsen B; Nielsen JO; Madsbad S; Iversen J
J Med Virol; 2005 Sep; 77(1):29-38. PubMed ID: 16032748
[TBL] [Abstract][Full Text] [Related]
25. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.
Saitoh A; Fenton T; Alvero C; Fletcher CV; Spector SA
Antimicrob Agents Chemother; 2007 Dec; 51(12):4236-42. PubMed ID: 17893156
[TBL] [Abstract][Full Text] [Related]
26. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
[TBL] [Abstract][Full Text] [Related]
27. [Impact of reverse transcriptase inhibitors on sperm mitochondrial and genomic DNA in assisted reproduction techniques].
Sergerie M; Martinet S; Kiffer N; Teulé R; Pasquier C; Bujan L
Gynecol Obstet Fertil; 2004 Oct; 32(10):841-9. PubMed ID: 15501159
[TBL] [Abstract][Full Text] [Related]
28. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
[TBL] [Abstract][Full Text] [Related]
29. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity.
Walker UA; Venhoff N
Antivir Ther; 2005; 10 Suppl 2():M117-23. PubMed ID: 16152713
[TBL] [Abstract][Full Text] [Related]
30. Impact of mitochondrial toxicity of HIV-1 antiretroviral drugs on lipodystrophy and metabolic dysregulation.
Feeney ER; Mallon PW
Curr Pharm Des; 2010 Oct; 16(30):3339-51. PubMed ID: 20687890
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy.
McComsey G; Tan DJ; Lederman M; Wilson E; Wong LJ
AIDS; 2002 Mar; 16(4):513-8. PubMed ID: 11872993
[TBL] [Abstract][Full Text] [Related]
32. An introduction to nucleoside and nucleotide analogues.
Squires KE
Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
[TBL] [Abstract][Full Text] [Related]
33. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.
Pace CS; Martin AM; Hammond EL; Mamotte CD; Nolan DA; Mallal SA
Antivir Ther; 2003 Aug; 8(4):323-31. PubMed ID: 14518702
[TBL] [Abstract][Full Text] [Related]
34. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
[TBL] [Abstract][Full Text] [Related]
35. Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors.
Miller RF; Shahmonesh M; Hanna MG; Unwin RJ; Schapira AH; Weller IV
Antivir Ther; 2003 Jun; 8(3):253-7. PubMed ID: 12924544
[TBL] [Abstract][Full Text] [Related]
36. Mitochondrial dysfunction in HIV infection: an overview of pathogenesis.
Rustin P
J HIV Ther; 2001 Mar; 6(1):4-12. PubMed ID: 11501198
[No Abstract] [Full Text] [Related]
37. A brief review on human mtDNA mutations and NRTI-associated mtDNA toxicity and mutations.
Chattopadhyay K; Aldous C
Mitochondrial DNA A DNA Mapp Seq Anal; 2016 May; 27(3):1685-7. PubMed ID: 25211089
[TBL] [Abstract][Full Text] [Related]
38. Extensive investigations of mitochondrial DNA genome in treated HIV-infected subjects: beyond mitochondrial DNA depletion.
McComsey G; Bai RK; Maa JF; Seekins D; Wong LJ
J Acquir Immune Defic Syndr; 2005 Jun; 39(2):181-8. PubMed ID: 15905734
[TBL] [Abstract][Full Text] [Related]
39. Mitochondrial toxicity of nucleoside analogues: mechanism, monitoring and management.
Cherry CL; Lala L; Wesselingh SL
Sex Health; 2005; 2(1):1-11. PubMed ID: 16334706
[TBL] [Abstract][Full Text] [Related]
40. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
Nolan D; Hammond E; James I; McKinnon E; Mallal S
Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
